Join TriSalus Life Sciences for a virtual key opinion leader (KOL) event that will feature the findings of a newly published real-world outcomes study demonstrating that Pressure-Enabled Drug Delivery™ (PEDD™) delivered a 48% improvement in drug delivery to target tumors while reducing complications associated with  off-target administration when compared with conventional embolization approaches — results with meaningful implications for the estimated 900,000 patients diagnosed annually worldwide with primary liver tumors or liver metastases.

Alexander S. Misono, MD, MBA, RPVI, Chief of Interventional Radiology at Hoag Hospital (Newport Beach, CA), will join TriSalus management to discuss the current treatment landscape for hepatocellular carcinoma (HCC) and liver metastases, how the new real-world evidence shapes patient selection and treatment strategy, and share clinical experience and case examples using the TriNav® Infusion System.

A live Q&A session will follow the formal presentations, providing direct engagement with management and Dr. Misono.